

Amendments to the Claims:

This listing of the claims replaces all prior versions of the claims in the application:

Listing of the Claims:

1.-91. (Cancelled)

92. (Previously Presented) A penetrating module consisting of a penetrating peptide and an effector that is coupled or fused to said penetrating peptide, said penetrating peptide consisting of at least one amino acid sequence selected from the group consisting of:

- a) SEQ ID NO: 24 and;
- b) at least 12 contiguous amino acids of any of SEQ ID NO:24,

wherein said penetrating peptide is capable of translocating the effector across a biological barrier, wherein, when the effector is a polypeptide, the penetrating module is encoded by a chimeric gene sequence.

93. (Previously Presented) The penetrating module of claim 92, wherein said effector is a bioactive peptide.

94. (Currently Amended) The penetrating module of claim 93, wherein said bioactive peptide is ~~selected from the group consisting of: insulin, growth hormone, a gonadotropin, a growth factor, erythropoietin, granulocyte/monocyte colony stimulating factor (GM-CSF), α MSH, enkephalin, dalargin, kyotorphin, EPO, bFGF, hirulog, a lutenizing hormone releasing hormone (LHRH) analog, and neurotrophic factors.~~

95.-96. (Cancelled)

97. (Previously Presented) The penetrating module of claim 92, wherein translocation across a biological barrier occurs within a tissue selected from the group consisting of: epithelial cells and endothelial cells.

98. (Previously Presented) The penetrating module of claim 92, wherein said biological barrier is selected from the group consisting of: tight junctions and the plasma membrane.

99. (Previously Presented) A pharmaceutical composition comprising a therapeutically or prophylactically effective amount of the penetrating module of claim 92, and a pharmaceutically acceptable carrier.

100. (Currently Amended) The pharmaceutical composition of claim 99, wherein the composition further comprises ~~a mixture of at least two substances selected from the group consisting of a non-ionic detergent, an ionic detergent, a protease inhibitor, and a reducing agent.~~

101.-102 (Cancelled)

103. (Original) The pharmaceutical composition of claim 100, wherein the ionic detergent is a bile salt.

104. (Previously Presented) The pharmaceutical composition of claim 103, wherein the bile salt is Taurodeoxycholate.

105.-106. (Cancelled)

107. (Previously Presented) A kit for treating a disease or pathological condition comprising, in one or more containers, a therapeutically or prophylactically effective amount of the pharmaceutical composition of claim 99.

108.-125. (Cancelled)